💉 Wegovy Shows Promise Treating Serious Liver Disease in Global Trial




A Phase 3 clinical trial has found that Wegovy, a weight loss medication, can effectively treat metabolic dysfunction-associated steatohepatitis (MASH)—a severe form of fatty liver disease. The results, published in the New England Journal of Medicine, reveal that the drug reduced both inflammation and liver scarring in about two-thirds of the patients.

MASH, once known as nonalcoholic steatohepatitis, is a progression of metabolic dysfunction-associated steatotic liver disease (MASLD). This condition affects about 33% of U.S. adults, with 5–7% suffering from the more advanced form, MASH. It is more common in individuals with obesity or type 2 diabetes.

"This is fairly monumental and really is going to be paradigm-changing."
— Dr. Sobia Laique, Cleveland Clinic

If untreated, MASH can lead to fibrosis, liver failure, or cancer. Current treatments are limited, with resmetirom being the only FDA-approved drug—but it helps only a fraction of patients and doesn’t tackle root causes.

The trial enrolled 800 patients from 37 countries, administering either 2.4 mg of semaglutide (Wegovy's active ingredient) or a placebo weekly for 72 weeks.

  • 63% of the semaglutide group showed reduced liver inflammation (vs. 34.3% on placebo)

  • 37% saw improvement in fibrosis (vs. 22.4% on placebo)

  • Average weight loss in the semaglutide group was 10.5%


A reduction in inflammation and fibrosis was seen in many patients taking semaglutide (Illustration only)

"It's incredibly good news that semaglutide not only reduced inflammation but also reversed fibrosis." — Dr. Susan Spratt, Duke Health

This adds to the growing use of GLP-1 agonists like Wegovy and Ozempic in treating heart disease, kidney disease, sleep apnea, and potentially Alzheimer’s and alcohol addiction.

The FDA is expected to decide on Wegovy for MASH approval by late 2025, having granted it priority review (6 months instead of 9). While the drug was generally well tolerated, some reported nausea, vomiting, diarrhea, and constipation.

Experts remain cautiously optimistic: though results are encouraging, questions about long-term efficacy and the need for ongoing use remain.


Open Your Mind!!!

Source: NBC News

💉 Wegovy muestra resultados prometedores contra una enfermedad hepática grave en un ensayo global


Un ensayo clínico de fase 3 reveló que Wegovy, medicamento usado para la pérdida de peso, puede tratar eficazmente la esteatohepatitis metabólica (MASH), una forma grave de enfermedad hepática grasa. Los resultados, publicados en el New England Journal of Medicine, muestran reducción significativa de inflamación y fibrosis hepática en dos tercios de los pacientes.

MASH, antes conocida como esteatohepatitis no alcohólica, es una progresión de la enfermedad hepática grasa asociada a disfunción metabólica (MASLD). Afecta a un 33% de los adultos en EE.UU., siendo más común en personas con obesidad o diabetes tipo 2.

"Es algo monumental que podría cambiar el paradigma." — Dra. Sobia Laique, Cleveland Clinic

Sin tratamiento, MASH puede derivar en fibrosis, fallo hepático o cáncer. Solo existe un medicamento aprobado por la FDA, el resmetirom, que ayuda a menos del 25% de los pacientes y no trata las causas subyacentes.

El ensayo incluyó 800 pacientes de 37 países, que recibieron 2.4 mg de semaglutida (ingrediente activo de Wegovy) o un placebo semanal durante 72 semanas.

  • El 63% del grupo con semaglutida redujo la inflamación hepática (vs. 34.3% con placebo)

  • El 37% mostró mejoría en la fibrosis (vs. 22.4% con placebo)

  • La pérdida de peso promedio fue del 10.5%


Muchos pacientes con semaglutida mostraron reducción de la inflamación y fibrosis (Ilustración representativa)

"Es una excelente noticia que la semaglutida no solo redujo la inflamación, sino que revirtió la fibrosis." — Dra. Susan Spratt, Duke Health

Esto se suma a las crecientes aplicaciones de los agonistas GLP-1 como Wegovy y Ozempic en enfermedades del corazón, riñones, apnea del sueño, y posiblemente Alzhéimer y adicción al alcohol.

La FDA podría decidir aprobar Wegovy para MASH a finales de 2025, ya que le otorgó revisión prioritaria (6 meses en lugar de 9). Aunque el fármaco fue generalmente bien tolerado, se reportaron efectos secundarios como náuseas, vómitos, diarrea y estreñimiento.

Expertos se muestran optimistas pero cautelosos: aunque los resultados son alentadores, queda por comprobar si los beneficios se mantienen a largo plazo y si los pacientes deberán seguir tomando el medicamento indefinidamente.


Open Your Mind!!!

Source: NBC News

Comments

Post a Comment

Trending 🔥

Google’s Veo 3 AI Video Tool Is Redefining Reality — And The World Isn’t Ready

Image
Google’s Veo 3 AI Video Tool Is Redefining Reality — And The World Isn’t Ready In May 2025, Google unveiled Veo 3, its latest AI-powered video generation model, at the Google I/O event. This groundbreaking tool has rapidly transformed the landscape of digital content creation, enabling users to produce hyper-realistic videos complete with synchronized audio, dialogue, and sound effects—all from simple text or image prompts. As Veo 3 garners attention for its impressive capabilities, it also raises significant questions about the future of media authenticity, creative professions, and the ethical implications of AI-generated content. What Sets Veo 3 Apart? Veo 3 represents a significant leap forward in AI video generation technology. Unlike its predecessors and competitors, Veo 3 offers: Native Audio Integration: Veo 3 can generate synchronized audio, including dialogues, ambient sounds, and music, enhancing the realism of the videos.  High-Quality Visuals: The model produces vi...
Read more

Tiny Machines, Huge Impact: Molecular Jackhammers Wipe Out Cancer Cells

Image
  Tiny Machines, Huge Impact: Molecular Jackhammers Wipe Out Cancer Cells 1. A Revolutionary Cancer-Killing Tool Scientists from Rice University, Texas A&M, and the University of Texas MD Anderson have invented a radical tool that destroys 99% of cancer cells —without using drugs, radiation, or heat. Instead, it uses special dye molecules and gently applied light to physically rip cancer cells apart from the inside. This technique—nicknamed “molecular jackhammers” —has achieved astonishing results in lab cultures and animal studies. These molecular jackhammers are based on a familiar dye used in hospitals: aminocyanine . When exposed to near-infrared light , this dye vibrates at incredibly high frequencies—up to 1 trillion times per second. These vibrations break open cancer cell membranes, causing cells to collapse. Published in the journal Nature Chemistry , this discovery offers a new frontier in cancer treatment by physically destroying tumor cells rather than pois...
Read more

A New Kind of Life: Scientists Push the Boundaries of Genetics

Image
A New Kind of Life: Scientists Push the Boundaries of Genetics The strange idea of making life “better” It almost sounds like science fiction: a team of researchers in Cambridge claims they’ve created a form of life that’s leaner, more efficient, maybe even “more perfect” than anything nature has ever managed. That phrase more perfect is tricky, of course, because perfection in biology is a moving target. What works in one environment is useless in another. Still, the claim is bold. The scientists didn’t just tweak a gene here or there, like swapping out corn DNA to make it more pestresistant. They rewrote the actual structure of life’s code, stripping it down, removing what they saw as excess baggage. The result is something they call Syn57 : a genetically engineered strain of E. coli. Yes, the same bacterium you’ve probably heard about from grim foodsafety warnings. Only this version isn’t lurking on a questionable hot dogit’s a reimagined lifeform built line by line from altere...
Read more